Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

AstraZeneca unveiled promising new data for two of its cancer drugs — Enhertu and Tagrisso — giving the pharma giant the ...

Little Johnstons star Liz Johnston revealed her reaction to learning that her daughter, Leighton Drew, is a normal-sized baby ...

Before Liz announced that her daughter would be average height, her parents Trent and Amber Johnston had their fingers not-so ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.